Quantification of Cerebral Nicotinic Acetylcholine Receptors by PET Using 2-[18F]Fluoro-A-85380 and the Multiinjection Approach

The multiinjection approach was used to study in vivo interactions between α4β2* nicotinic acetylcholine receptors and 2-[18F]fluoro-A-85380 in baboons. The ligand kinetics was modeled by the usual nonlinear compartment model composed of three compartments (arterial plasma, free and specifically bound ligand in tissue). Arterial blood samples were collected to generate a metabolite-corrected plasma input function. The experimental protocol, which consisted of three injections of labeled or unlabeled ligand, was aiming at identifying all parameters in one experiment. Various parameters, including B'max (the binding sites density) and KdVR (the apparent in vivo affinity of 2-[18F]fluoro-A-85380) could then be estimated in thalamus and in several receptor-poor regions. B'max estimate was 3.0±0.3 pmol/mL in thalamus, and ranged from 0.25 to 1.58 pmol/ml_ in extrathalamic regions. Although KdVR could be precisely estimated, the association and dissociation rate constants kon/VR and koff could not be identified separately. A second protocol was then used to estimate koff more precisely in the thalamus. Having estimated all model parameters, we performed simulations of 2-[18F]fluoro-A-85380 kinetics to test equilibrium hypotheses underlying simplified approaches. These showed that a pseudo-equilibrium is quickly reached between the free and bound compartments, a favorable situation to apply Logan graphical analysis. In contrast, the pseudo-equilibrium between the plasma and free compartments is only reached after several hours. The ratio of radioligand concentration in these two compartments then overestimates the true equilibrium value, an unfavorable situation to estimate distribution volumes from late images after a bolus injection.

[1]  N. Alpert,et al.  Concentration of dopamine transporters: To Bmax or not to Bmax? , 1999, Synapse.

[2]  V. O. Wagner,et al.  Pharmacological and Toxicological Evaluation of 2-Fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-F-A-85380), a Ligand for Imaging Cerebral Nicotinic Acetylcholine Receptors with Positron Emission Tomography , 2005, Journal of Pharmacology and Experimental Therapeutics.

[3]  Karmen K. Yoder,et al.  Estimation of local receptor density, B'max, and other parameters via multiple-injection positron emission tomography experiments. , 2004, Methods in enzymology.

[4]  C. Gotti,et al.  Neuronal nicotinic receptors: from structure to pathology , 2004, Progress in Neurobiology.

[5]  A. Sato,et al.  Effect of stimulation of nicotinic cholinergic receptors on cortical cerebral blood flow and changes in the effect during aging in anesthetized rats , 1997, Neuroscience Letters.

[6]  Yu-Shin Ding,et al.  Modeling and analysis of PET studies with norepinephrine transporter ligands: the search for a reference region. , 2005, Nuclear medicine and biology.

[7]  R H Huesman,et al.  Dynamic PET Data Analysis , 1986, Journal of computer assisted tomography.

[8]  James V. Beck,et al.  Parameter Estimation in Engineering and Science , 1977 .

[9]  A. Syrota,et al.  Kinetics of in vivo binding of antagonist to muscarinic cholinergic receptor in the human heart studied by positron emission tomography. , 1984, Life sciences.

[10]  A. Nordberg,et al.  Quantitative autoradiography of nicotinic receptors in large cryosections of human brain hemispheres , 1989, Neuroscience Letters.

[11]  E. Perry,et al.  Molecular analysis of nicotinic receptor expression in autism. , 2004, Brain research. Molecular brain research.

[12]  D E Kuhl,et al.  Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  Bernard Bendriem,et al.  Modeling Analysis of [11C]Flumazenil Kinetics Studied by PET: Application to a Critical Study of the Equilibrium Approaches , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  K. B. Larson,et al.  Strategies for in vivo Measurement of Receptor Binding Using Positron Emission Tomography , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  Felix Franks,et al.  In-Vitro Characterization of mCerulean3_mRuby3 as a Novel FRET Pair with Favorable Bleed-Through Characteristics , 2019, Biosensors.

[16]  S. Potkin,et al.  Synthesis and Evaluation of Nicotine 42 Receptor Radioligand, 5-(3- 18 F-Fluoropropyl)-3- (2-(S)-Pyrrolidinylmethoxy)Pyridine, in Rodents and PET in Nonhuman Primate , 2005 .

[17]  R. Waterhouse,et al.  Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[18]  R. Egleton,et al.  Modulation of cerebral microvascular permeability by endothelial nicotinic acetylcholine receptors. , 2005, American journal of physiology. Heart and circulatory physiology.

[19]  A. Saija,et al.  Modifications of the permeability of the blood-brain barrier and local cerebral metabolism in pentobarbital- and ketamine-anaesthetized rats , 1989, Neuropharmacology.

[20]  M Slifstein,et al.  Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. , 2001, Nuclear medicine and biology.

[21]  A. Nordberg,et al.  Autoradiographic comparison of [3H](−)nicotine, [3H]cytisine and [3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease , 1999, Neuroscience.

[22]  C. Crouzel,et al.  Synthesis of 2‐[18F]fluoro‐3‐[2(S)‐2‐azetidinylmethoxy]pyridine, a highly potent radioligand for in vivo imaging central nicotinic acetylcholine receptors , 1998 .

[23]  S. Arneric,et al.  Nicotinic agonists modulate basal forebrain control of cortical cerebral blood flow in anesthetized rats. , 1993, The Journal of pharmacology and experimental therapeutics.

[24]  A. Nordberg,et al.  Development of ligands for in vivo imaging of cerebral nicotinic receptors , 2000, Behavioural Brain Research.

[25]  E. Perry,et al.  Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. , 2004, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[26]  B. Mazoyer,et al.  Noninvasive quantification of muscarinic receptors in vivo with positron emission tomography in the dog heart. , 1990, Circulation.

[27]  M E Phelps,et al.  Neuroreceptor Assay with Positron Emission Tomography: Equilibrium versus Dynamic Approaches , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  C Crouzel,et al.  Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors. , 1999, Journal of medicinal chemistry.

[29]  O. Steinlein Nicotinic acetylcholine receptors and epilepsy. , 2002, Current drug targets. CNS and neurological disorders.

[30]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  L. Farde,et al.  Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[32]  Agneta Nordberg,et al.  Neuronal nicotinic receptors in the human brain , 2000, Progress in Neurobiology.

[33]  N. Volkow,et al.  Effects of Blood Flow on [11C]Raclopride Binding in the Brain: Model Simulations and Kinetic Analysis of PET Data , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[34]  E. Eger The pharmacology of isoflurane. , 1984, British journal of anaesthesia.

[35]  Agneta Nordberg,et al.  [3H]Acetylcholine nicotinic recognition sites in human brain: Characterization of agonist binding , 1987, Neuroscience Letters.

[36]  J. Links,et al.  6-[18F]fluoro-A-85380, a novel radioligand for in vivo imaging of central nicotinic acetylcholine receptors. , 2000, Life sciences.

[37]  Paul A. Viola,et al.  Alignment by Maximization of Mutual Information , 1997, International Journal of Computer Vision.

[38]  G. Sedvall,et al.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.

[39]  Jean-Dominique Gallezot,et al.  In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  E. London,et al.  2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. , 1998, Journal of medicinal chemistry.

[41]  R. Traystman,et al.  Cerebral Blood Flow in Primates Is Increased by Isoflurane over Time and Is Decreased by Nitric Oxide Synthase Inhibition , 1994, Anesthesiology.

[42]  A. R. Banknieder,et al.  Comparison of ketmine with the combination of ketamine and xylazine for effective anesthesia in the rhesus monkey (Macaca mulatta). , 1978, Laboratory animal science.

[43]  G. Saidel,et al.  Iterative optimal design of PET experiments for estimating β-adrenergic receptor concentration , 2000, Medical and Biological Engineering and Computing.

[44]  M. Quik,et al.  Declines in Different β2* Nicotinic Receptor Populations in Monkey Striatum after Nigrostriatal Damage , 2002, Journal of Pharmacology and Experimental Therapeutics.

[45]  Banknieder Ar,et al.  Comparison of ketmine with the combination of ketamine and xylazine for effective anesthesia in the rhesus monkey (Macaca mulatta). , 1978 .

[46]  D Wyper,et al.  Nicotinic Acetylcholine Receptor Distribution in Alzheimer's Disease, Dementia with Lewy Bodies, Parkinson's Disease, and Vascular Dementia: In Vitro Binding Study Using 5-[125I]-A-85380 , 2004, Neuropsychopharmacology.

[47]  T. Abbruscato,et al.  Nicotine and cotinine modulate cerebral microvascular permeability and protein expression of ZO-1 through nicotinic acetylcholine receptors expressed on brain endothelial cells. , 2002, Journal of pharmaceutical sciences.

[48]  G. J. Crystal,et al.  Regional blood flow in canine brain during nicotine infusion: effect of autonomic blocking drugs. , 1983, Stroke.

[49]  Edythe D London,et al.  Graphical analysis of 2‐[18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain , 2003, Synapse.

[50]  N. Kassell,et al.  Comparison of systemic and cerebrovascular effects of isoflurane and halothane. , 1984, Neurosurgery.

[51]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[52]  J Delforge,et al.  Experimental design optimisation: theory and application to estimation of receptor model parameters using dynamic positron emission tomography. , 1989, Physics in medicine and biology.

[53]  D. Wieland,et al.  Concentration of dopamine analogs in the adrenal medulla. , 1975, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  N. Alpert,et al.  Comparison of Two Compartmental Models for Describing Receptor Ligand Kinetics and Receptor Availability in Multiple Injection PET Studies , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[55]  R. Friedland,et al.  PET quantification of specific binding of carbon-11-nicotine in human brain. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  Peter Herscovitch,et al.  Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission Tomography , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[57]  F. Dollé,et al.  Fluoro-A-85380 demonstrated no mutagenic properties in in vivo rat micronucleus and Ames tests. , 2002, Nuclear medicine and biology.

[58]  R. Egleton,et al.  Nicotine increases in vivo blood–brain barrier permeability and alters cerebral microvascular tight junction protein distribution , 2004, Brain Research.

[59]  C. Gotti,et al.  Human neuronal nicotinic receptors , 1997, Progress in Neurobiology.

[60]  Agneta Nordberg,et al.  Regional distribution of subtypes of nicotinic receptors in human brain and effect of aging studied by (±)-[3 H]epibatidine , 1998, Brain Research.

[61]  D E Kuhl,et al.  Differentiation of Radioligand Delivery and Binding in the Brain: Validation of a Two-Compartment Model for [11C]Flumazenil , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[62]  S. Potkin,et al.  Synthesis and evaluation of nicotine alpha4beta2 receptor radioligand, 5-(3'-18F-fluoropropyl)-3-(2-(S)-pyrrolidinylmethoxy)pyridine, in rodents and PET in nonhuman primate. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[63]  C. Crouzel,et al.  Characterization of the nicotinic ligand 2-[18F]fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine in vivo. , 1998, Life sciences.

[64]  G Brix,et al.  Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[65]  Edythe D London,et al.  Pharmacological and Toxicological Evaluation of 2-Fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-F-A-85380), a Ligand for Imaging Cerebral Nicotinic Acetylcholine Receptors with Positron Emission Tomography , 2005, Journal of Pharmacology and Experimental Therapeutics.

[66]  Marcel Ricard,et al.  Biodistribution and radiation dosimetry of 18F-fluoro-A-85380 in healthy volunteers. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[67]  C Crouzel,et al.  Imaging central nicotinic acetylcholine receptors in baboons with [18F]fluoro-A-85380. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[68]  J M Links,et al.  In vivo imaging of brain nicotinic acetylcholine receptors with 5-[123I]iodo-A-85380 using single photon emission computed tomography. , 1998, Life sciences.

[69]  D. Marquardt An Algorithm for Least-Squares Estimation of Nonlinear Parameters , 1963 .

[70]  J Delforge,et al.  Concept of reaction volume in the in vivo ligand-receptor model. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[71]  Lee W. Schruben,et al.  Modeling & Analysis , 2003, NeuroImage.

[72]  Bernard Bendriem,et al.  Quantitation of Extrastriatal D2 Receptors Using a Very High-Affinity Ligand (FLB 457) and the Multi-Injection Approach , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[73]  Y. Magata,et al.  Evaluation of 5-11C-Methyl-A-85380 as an Imaging Agent for PET Investigations of Brain Nicotinic Acetylcholine Receptors , 2004 .

[74]  H. Weiss,et al.  Effects of isoflurane on transport across the blood-brain barrier. , 1992, Anesthesiology.